Evommune (EVMN) Revenue (2025)
Evommune (EVMN) posted quarterly Revenue of $10.0 million for Q3 2025, up 233.33% quarter-over-quarter from $3.0 million in Q1 2025.
Powered by 
Analysis
Evommune (EVMN) Revenue (2025) Analysis & Trends
Evommune (EVMN) has reported Revenue for 1 consecutive years, with $10.0 million the latest figure, recorded in Q3 2025.
- In Q3 2025, Revenue changed N/A year-over-year to $10.0 million; the TTM figure through Mar 2026 stood at $13.0 million (changed N/A YoY), while the FY2025 annual figure was $13.0 million, up 85.71% from the prior year.
- Revenue advanced to $10.0 million in Q3 2025 per EVMN's latest filing, from $3.0 million in the prior quarter.
- Across five years, Revenue topped out at $10.0 million in Q3 2025 and bottomed at $3.0 million in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.62 Bn | 131.77 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 85.73 Bn | 77.73 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 63.53 Bn | 58.35 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.23 Bn | 53.09 Bn | 52.00 Mn | 145.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | - |
| 6 | BeOne Medicines | 40.03 Bn | 34.93 Bn | 1.53 Bn | 1.71 Bn |
| 7 | Alnylam Pharmaceuticals | 35.50 Bn | 32.19 Bn | 992.69 Mn | 1.29 Bn |
| 8 | Royalty Pharma | 28.52 Bn | 27.68 Bn | - | 674.14 Mn |
| 9 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Evommune | 441.58 Mn | 240.78 Mn | - | - |